Generic Name and Formulations:
Haemophilus b conjugate vaccine (diphtheria CRM197 conjugate) 10mcg capsular oligosaccharides, 25mcg diphtheria CRM197 protein; per 0.5mL dose; IM inj; multidose vials contain thimerosal.
Indications for HIBTITER:
Immunization of children against H. influenza type b.
<2 months: not recommended. At 2, 4, and 6 months: 0.5mL IM. Previously unvaccinated children, 7–11 months: 2 doses of 0.5mL IM 2 months apart. 12–14 months: 0.5mL IM once. All children vaccinated before 15 months of age should receive booster at 15 months (but not less than 2 months after previous shot). 15–60 months: 0.5mL IM once.
Immunodeficiency (HIV infection: see literature). Delay administration in febrile or active infection. Have epinephrine inj (1:1000) available. Protection begins several days after vaccination. Not a substitute for routine diphtheria vaccination. Pregnancy (Cat.C): not recommended.
Local reactions, fever.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|